Login to Your Account

Other News To Note

Friday, June 3, 2011
Opexa Therapeutics Inc., of The Woodlands, Texas, met with Health Canada's Biologics and Genetics Therapies Directorate to review the status of its cellular therapy for multiple sclerosis, Tovaxin. The company received guidance from the agency regarding its plan to carry out Phase III trials at some Canadian sites. A positive review is required before it can initiate a clinical study.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription